Pierre Saintigny



  1. Foy J, Pickering C, Papadimitrakopoulou V, Jelinek J, Lin S, William W, et al. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prev Res (Phila). 2015;8:1027-35 pubmed publisher
    ..0153). In conclusion, AGTR1, FOXI2, and PENK promoter methylation and LINE1 hypomethylation may be associated with an increased risk of OSCC development in patients with OPLs. ..
  2. Hofman P, Ayache N, Barbry P, Barlaud M, Bel A, Blancou P, et al. The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again. Cancers (Basel). 2019;11: pubmed publisher
    ..This review outlines the broad strategic directions and key advances of OncoAge and summarizes some of the issues faced by this consortium, as well as the short- and long-term perspectives. ..
  3. Tan F, Bai Y, Saintigny P, Darido C. mTOR Signalling in Head and Neck Cancer: Heads Up. Cells. 2019;8: pubmed publisher
    ..In this review, we discuss how these mutant genes could affect mTOR signalling and highlight their impact on metabolic processes, as well as suggest potential targets for therapeutic intervention, primarily in head and neck cancer. ..
  4. Albaret M, Vermot Desroches C, Paré A, Roca Martinez J, Malet L, Esseily J, et al. Externalized Keratin 8: A Target at the Interface of Microenvironment and Intracellular Signaling in Colorectal Cancer Cells. Cancers (Basel). 2018;10: pubmed publisher
  5. Hamant C, Deneuve S, Albaret M, Zrounba P, Breton P, Ceruse P, et al. [Smoking and alcohol cessation programs in patients with head and neck cancer]. Bull Cancer. 2018;105:1012-1019 pubmed publisher
    ..More work is ongoing within the context of our IHNPACT umbrella protocol to identify hurdles associated with successful ASC. ..
  6. Saintigny P, Foy J, Ferrari A, Cassier P, Viari A, Puisieux A. [Contribution and challenges of Big Data in oncology]. Bull Cancer. 2017;104:281-287 pubmed publisher
    ..Here, we describe the contribution and challenges of Big Data in oncology. ..
  7. Foy J, Bazire L, Ortiz Cuaran S, Deneuve S, Kielbassa J, Thomas E, et al. A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes. BMC Med. 2017;15:165 pubmed publisher
    ..Our study highlights the clinical relevance of the molecular classification of HNSCC and the RadR score to refine radiation strategies in HPV-negative disease. ..